Sangamo BioSciences | SGMO - Operating Expenses


Sangamo BioSciences reported $33.87M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Alaunos Therapeutics USD 952K 60K Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amgen USD 5.69B 6B Sep/2026
Bayer EUR 9.92B 121M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Cipla INR 63.61B 1.3B Sep/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.44M 246K Jun/2026
CSL USD 5.7B 2.82B Dec/2025
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Grifols EUR 1.99B 217.4M Dec/2025
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 9.88B 325M Sep/2026
Omeros USD 59.16M 20.13M Jun/2024
Pfizer USD 89B 3.81B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 598M Sep/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Tectonic Therapeutic USD 24.22M 3.08M Jun/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026